Whalesbook
An analyst at HDFC Securities has outlined specific options trading strategies aimed at capturing potential gains in the Midcap Nifty index and Sun Pharma stock, while carefully managing risk. These trades, known as bull spreads, are favored by the analyst due to observed positive technical trends and activity in futures markets. The use of spreads suggests an expectation of upward movement within a certain price range, rather than unlimited upside.
Midcap Nifty Bull Spread Strategy
For the Midcap Nifty, the recommended trade involves buying the 14,000 Call option and selling the 14,200 Call option, both with a May 26 expiry. This strategy offers a maximum potential profit of ₹14,400 if the index closes at or above 14,200. The maximum possible loss is limited to ₹9,600 if the index closes below 14,000. The breakeven point for this trade is 14,080, providing a risk-reward ratio of approximately 1:1.5. The trade requires an estimated margin of ₹33,000.
Sun Pharma Bull Spread Strategy
For Sun Pharma, the recommended strategy also uses the May 26 expiry. It involves buying the 1,820 Call option and selling the 1,860 Call option. This trade has a maximum profit limit of ₹8,050 if Sun Pharma's stock price closes at or above 1,860. The maximum loss is capped at ₹5,950 if the stock falls below 1,820. The breakeven point is 1,837, with a risk-reward ratio of about 1:1.35. This strategy requires an estimated margin of ₹22,000. The analyst advises booking profits on both trades when the return on investment reaches 20%.
Rationale Behind the Picks
The analyst's reasoning for recommending these bullish trades is based on a noticeable 'long build-up' in the futures contracts for both Midcap Nifty and Sun Pharma. For the Midcap Nifty, open interest increased by 6%, accompanied by a price rise of over 1.5%. The index is trading above its 100-day and 200-day moving averages, indicating a positive overall trend. Additionally, substantial buying interest in put options at the 13,800-14,000 levels suggests strong support.
Sun Pharma's futures also showed a long build-up, with open interest increasing alongside an 1.80% price jump. The stock's short-term trend is supported by its position above the 5-day and 20-day moving averages. Technical indicators are also trending upward and holding above the 50 mark, signaling continued strength. The stock has seen breakouts on its charts on daily and weekly scales, supported by increased trading volumes.
Potential Risks and Cautionary Notes
Despite the bullish recommendations, a closer look reveals potential risks. Sun Pharma's short-term technical signals rely on moving averages that could quickly reverse. The stock has recently traded below its 5, 20, 50, 100, and 200-day moving averages, suggesting a weaker overall technical picture than the short-term indicators imply. On April 24, Sun Pharma saw a 2.49% drop, closing at ₹1,646.7, indicating that high trading volumes do not always guarantee price increases.
Broader market challenges also exist. Foreign institutional investors have been net sellers in April, adding selling pressure. The Indian Rupee has reached record lows against the US dollar amid rising crude oil prices, creating economic uncertainty. While the Midcap Nifty shows positive signs, technical indicators like the RSI (44.722) and MACD (-147.740) on the Nifty Midcap 100 index suggest caution. Additionally, the nature of bull spreads means potential profits are limited, even if the underlying asset surges significantly, meaning investors could miss out on larger market rallies.
Analyst Views and Future Projections
Looking ahead, analysts generally hold a positive view on Sun Pharma. The consensus rating is 'BUY', with an average 12-month price target of around ₹1,990.91, suggesting a potential upside of more than 10%. This outlook is driven by the company's strong earnings growth prospects and its focus on higher-margin specialty products. For the broader market, projections suggest a cautiously optimistic sentiment for early May 2026, with the Nifty expected to face resistance near 24,200. Opportunities are also anticipated in the mid-cap segment, with analysts identifying specific stocks that could deliver strong returns.